Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer
Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (<i>n</i> = 85), 182 circulating cytokines were teste...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/24/5823 |
| _version_ | 1797381656037818368 |
|---|---|
| author | Irene Assaf Danai Fimereli Geraldine Anthoine Roberta Fazio Valentina Daprà Alessandro Audisio Alina Bardiaux Tugba Akin Telli Michele Vanhooren Rita Saude-Conde Giacomo Bregni Alain Hendlisz Francesco Sclafani |
| author_facet | Irene Assaf Danai Fimereli Geraldine Anthoine Roberta Fazio Valentina Daprà Alessandro Audisio Alina Bardiaux Tugba Akin Telli Michele Vanhooren Rita Saude-Conde Giacomo Bregni Alain Hendlisz Francesco Sclafani |
| author_sort | Irene Assaf |
| collection | DOAJ |
| description | Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (<i>n</i> = 85), 182 circulating cytokines were tested with a semi-quantitative multiplex assay, and prognostic cytokines were analyzed in the validation cohort (<i>n</i> = 111) by ELISA. Overall survival (OS) was the primary outcome measure, with the false discovery rate (FDR) method (significance level of <0.01) being used to correct for multiple comparisons. Four cytokines were associated with OS in the discovery cohort: insulin-like growth factor-binding protein 1 (IGFBP-1) (HR 2.1 [95%CI: 1.58–2.79], FDR < 0.001), insulin-like growth factor-binding protein 2 (IGFBP-2) (HR 1.65 [95%CI: 1.28–2.13], FDR = 0.006), serum amyloid A (SAA) (HR 1.84 [95%CI: 1.39–2.43], FDR < 0.001), and angiotensin II (HR 1.65 [95%CI: 1.29–2.1], FDR = 0.006). Of these, IGFBP-1 (HR 2.70 [95%CI: 1.56–4.76], FDR = 0.007) and IGFBP-2 (HR 3.33 [95%CI: 1.64–6.67], FDR = 0.008) were confirmed to be independently associated with OS in the validation cohort. Patients with high concentrations of IGFBP-1 and/or IGFBP-2 had a median OS of 3.0 months as compared with 6.9 months for those with low concentrations of both cytokines (HR 2.44 [95%CI: 1.52–4.0], FDR = 0.002) Validation of circulating IGFBP-1 and IGFBP-2 as independent prognostic biomarkers for chemorefractory CRC in larger, independent series is warranted. |
| first_indexed | 2024-03-08T20:55:35Z |
| format | Article |
| id | doaj.art-3d12b604729443468cf5fd86b686d75c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T20:55:35Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3d12b604729443468cf5fd86b686d75c2023-12-22T13:58:59ZengMDPI AGCancers2072-66942023-12-011524582310.3390/cancers15245823Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal CancerIrene Assaf0Danai Fimereli1Geraldine Anthoine2Roberta Fazio3Valentina Daprà4Alessandro Audisio5Alina Bardiaux6Tugba Akin Telli7Michele Vanhooren8Rita Saude-Conde9Giacomo Bregni10Alain Hendlisz11Francesco Sclafani12Department of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumBreast Cancer Translational Laboratory, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumGI Cancer Laboratory, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumGI Cancer Laboratory, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumDepartment of Digestive Oncology, Institut Jules Bordet, The Brussels University Hospital, 1070 Brussels, BelgiumCirculating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (<i>n</i> = 85), 182 circulating cytokines were tested with a semi-quantitative multiplex assay, and prognostic cytokines were analyzed in the validation cohort (<i>n</i> = 111) by ELISA. Overall survival (OS) was the primary outcome measure, with the false discovery rate (FDR) method (significance level of <0.01) being used to correct for multiple comparisons. Four cytokines were associated with OS in the discovery cohort: insulin-like growth factor-binding protein 1 (IGFBP-1) (HR 2.1 [95%CI: 1.58–2.79], FDR < 0.001), insulin-like growth factor-binding protein 2 (IGFBP-2) (HR 1.65 [95%CI: 1.28–2.13], FDR = 0.006), serum amyloid A (SAA) (HR 1.84 [95%CI: 1.39–2.43], FDR < 0.001), and angiotensin II (HR 1.65 [95%CI: 1.29–2.1], FDR = 0.006). Of these, IGFBP-1 (HR 2.70 [95%CI: 1.56–4.76], FDR = 0.007) and IGFBP-2 (HR 3.33 [95%CI: 1.64–6.67], FDR = 0.008) were confirmed to be independently associated with OS in the validation cohort. Patients with high concentrations of IGFBP-1 and/or IGFBP-2 had a median OS of 3.0 months as compared with 6.9 months for those with low concentrations of both cytokines (HR 2.44 [95%CI: 1.52–4.0], FDR = 0.002) Validation of circulating IGFBP-1 and IGFBP-2 as independent prognostic biomarkers for chemorefractory CRC in larger, independent series is warranted.https://www.mdpi.com/2072-6694/15/24/5823cytokinesIGFBP-1IGFBP-2colorectal cancer |
| spellingShingle | Irene Assaf Danai Fimereli Geraldine Anthoine Roberta Fazio Valentina Daprà Alessandro Audisio Alina Bardiaux Tugba Akin Telli Michele Vanhooren Rita Saude-Conde Giacomo Bregni Alain Hendlisz Francesco Sclafani Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer Cancers cytokines IGFBP-1 IGFBP-2 colorectal cancer |
| title | Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer |
| title_full | Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer |
| title_fullStr | Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer |
| title_full_unstemmed | Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer |
| title_short | Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer |
| title_sort | prognostic value of circulating cytokines in chemorefractory colorectal cancer |
| topic | cytokines IGFBP-1 IGFBP-2 colorectal cancer |
| url | https://www.mdpi.com/2072-6694/15/24/5823 |
| work_keys_str_mv | AT ireneassaf prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT danaifimereli prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT geraldineanthoine prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT robertafazio prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT valentinadapra prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT alessandroaudisio prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT alinabardiaux prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT tugbaakintelli prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT michelevanhooren prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT ritasaudeconde prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT giacomobregni prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT alainhendlisz prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer AT francescosclafani prognosticvalueofcirculatingcytokinesinchemorefractorycolorectalcancer |